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Etiology and epidemiology
Lyme arthritis was recognized as a clinical entity in 1976
when researchers at Yale University investigated a cluster
of arthritis in children from the three contiguous communi-
ties of Old Lyme, Lyme, and East Haddam, Connecticut
[1]. It was soon discovered that Lyme arthritis was only
one aspect of the clinical spectrum of Lyme disease and
that some manifestations of the disease had been
described in Europe early in the 20th century [2–4]. Ratio-
nal treatment for Lyme disease became possible after a
tick-borne spirochete, Borrelia burgdorferi, was identified
as the cause of Lyme disease [5,6].
Lyme disease is the most common vector-borne disease
in the United States, where approximately 15,000 cases
are reported every year [7]. The disease has a highly focal
distribution pattern, with over 90% of the cases reported
from eight states along the Atlantic Coast and from Wis-
consin. The annual reported incidence in these areas
ranges from 20 to slightly more than 100 cases per
100,000 inhabitants. In some areas the incidence may be
as high as 1000 cases per 100,000 inhabitants. The inci-
dence in children aged 5–10 years is approximately twice
as high as that in adults [7].
In Europe most cases occur in Scandinavia and Central
Europe. A prospective, population-based survey in
southern Sweden revealed an annual incidence of 69
cases per 100,000 population. As in the United States,
there were areas of endemicity in which the annual inci-
dence reached 160 per 100,000 inhabitants [8]. A
similar study in southern Germany found an annual inci-
dence of 111 cases per 100,000 inhabitants. The inci-
dence in children was higher than that in adults in both
these European studies [9].
B. burgdorferi is maintained in enzootic cycles between
ixoid ticks (Ixodes ricinus in Europe, and Ixodes scapularis
and  Ixodes pacificus in the United States) and small
mammal reservoirs. In addition to B. burgdorferi, the ixoid
ticks may carry other pathogens such as viruses, Babesia,
or the agent of human granulocytic ehrlichiosis [10].
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Lyme disease is a tick-borne multisystem disease that affects primarily the skin, nervous system, heart
and joints. At least three species of Borrelia burgdorferi sensu lato, namely Borrelia burgdorferi sensu
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Microbiology
B. burgdorferi sensu lato is a Gram-negative spirochete.
At least three species are known to be human pathogens:
B. burgdorferi sensu stricto, Borrelia garinii, and Borrelia
afzelii. The taxonomy and molecular typing of B. burgdor-
feri have recently been reviewed in detail [11]. Whereas
all three species occur in Europe, only B. burgdorferi
sensu stricto occurs in the United States. It has been sug-
gested that the different clinical manifestations were
caused by distinct species of B. burgdorferi sensu lato.
Based on DNA amplification, the late dermatologic mani-
festation acrodermatitis chronica atrophicans (ACA),
which is observed in Europe but rarely, if ever, in the
United States, was mostly but not exclusively associated
with B. afzelii [12]. Neuroborreliosis is frequently but not
exclusively caused by B. garinii [13], and all three species
have been detected in synovial fluid samples from patients
with Lyme arthritis [14].
The genome of B. burgdorferi sensu stricto (strain B31)
has been sequenced. The B. burgdorferi genome contains
853 genes distributed on a linear chromosome of
~920,000 base pairs and at least 17 linear and circular
plasmids with another ~530,000 base pairs [15].
B. burgdorferi does not contain the enzymes necessary for
the production of lipopolysaccharide [15]. The B. burgdor-
feri genome instead contains ~130 genes coding for
lipoproteins [15]. The lipid moiety is formed by the post-
translational attachment of tripalmitoyl-S-glyceryl-cysteine.
The outer surface proteins (Osps) are anchored to the
spirochete’s outer membrane via these lipid moieties. The
Osps bind the Toll like receptor-2 and are potent activa-
tors of the innate immune system [16,17].
The Osps are differentially expressed in different hosts
[18]. OspA and OspC are the most intensively studied
B. burgdorferi Osps, and the change from OspA expres-
sion to OspC expression seems to be important for the
migration of B. burgdorferi from the tick’s midgut to the
salivary gland and for the subsequent invasion of the mam-
malian host [19].
B. burgdorferi may persist in the host for many years and
has been isolated from an ACA lesion more than 10 years
after the initial symptoms [20]. B. burgdorferi can also
reinfect the same host [21].
Clinical manifestations
The clinical manifestations of Lyme disease have been
reviewed in a recent series of excellent reviews [21–23]
and will be described here only briefly. The clinical mani-
festations of Lyme disease are frequently categorized as
early localized disease (erythema migrans [EM]), followed
days or weeks later by early disseminated disease (e.g.
Bell’s palsy, arthralgia/arthritis) and late disease (e.g.
subtle encephalopathy, treatment-resistant Lyme arthritis).
Dermatological symptoms
EM is a slowly expanding erythematous papule or macule,
often with central clearing, and is diagnostic for early Lyme
disease. EM occurs within days or several weeks at the
site of the tick bite and may be accompanied by flu-like
symptoms. It is recognized in at least 80% of the patients
with objective evidence of B. burgdorferi infection [21,22].
In Europe, ACA is a late dermatologic manifestation of
Lyme disease.
Neurological symptoms
Approximately 10–15% of untreated patients with EM
develop neurological symptoms of Lyme disease. Early
neurological symptoms occur within weeks after the infec-
tion (early disseminated disease). The most common
symptom is facial palsy, either unilateral or bilateral. Other
early neurological symptoms include lymphocytic meningi-
tis, mild encephalitis and mononeuritis multiplex. These
symptoms typically resolve even in untreated patients
[21,22].
Late or chronic neuroborreliosis occurs in approximately
5% of untreated patients. Typical manifestations include
chronic axonal neuropathy and a subtle encephalopathy,
which can occur after months or years of latent infection
[21,22].
Cardiological symptoms
Less than 8% of untreated EM patients develop cardiolog-
ical symptoms. The typical feature is a transient atrioven-
tricular block of varying degrees [21,22]. In Europe, but
not in the United States, B. burgdorferi has been isolated
from endomyocardial biopsies from patients with dilatative
cardiomyopathy [24].
Lyme arthritis
Approximately 60% of untreated EM patients develop inter-
mittent attacks of monoarticular or oligoarticular arthritis,
primarily in large joints. Most patients with Lyme arthritis
respond to antibiotic therapy; however, in ~10% of
patients with Lyme arthritis, the inflammation persists
despite antibiotic therapy [21,23]. The synovial lesion in
treatment-resistant Lyme arthritis resembles that of other
chronic arthritides such as rheumatoid arthritis, including
the formation of germinal center like structures within the
inflamed synovium [21]. The incidence of treatment-resis-
tant Lyme arthritis is lower in children than in adults
[25,26]. In Europe, both B. burgdorferi sensu stricto and B.
garinii can cause treatment-resistant Lyme arthritis [27].
Patients who had been treated with steroids, either sys-
temically or intra-articularly, before Lyme arthritis was diag-
nosed and the appropriate antibiotic treatment
administered have an increased risk of developing treat-
ment-resistant Lyme arthritis [26,28]. In addition, host
factors may be crucial for the pathogenesis of treatment-Arthritis Research    Vol 4 No 1 Kamradt
resistant Lyme arthritis. B. burgdorferi DNA can be ampli-
fied reliably from synovial fluid prior to antibiotic treatment
[29]. In contrast, most patients with treatment-resistant
Lyme arthritis yield consistently negative PCR results in
synovial fluid after antibiotic treatment [29–31]. Whereas
B. burgdorferi DNA can be amplified from synovial tissue
in a minority of such patients [30], most patients yield neg-
ative results from both synovial fluid and synovial tissue
[31]. It therefore seems possible that chronic synovitis is
maintained in the absence of B. burgdorferi.
HLA-DR4 was found to be associated with a lack of
response to antibiotic therapy [32,33]. Both the severity
and the duration of Lyme arthritis are increased in patients
with IgG antibodies against OspA [33,34]. B. burgdorferi-
specific T cell lines from patients with treatment-responsive
arthritis recognized OspA only infrequently. In contrast, T
cell lines from patients with treatment-resistant arthritis
preferentially recognized OspA [35], and these patients
dominantly recognized certain OspA epitopes [36,37].
These findings are compatible with the idea that an HLA-
DR4-restricted immune response against B. burgdorferi
triggers an autoimmune synovitis, which persists even in
the absence of B. burgdorferi. These pathophysiological
considerations are discussed later.
Diagnosis
The Centers for Disease Control (CDC) have published a
case definition for Lyme disease, which combines clinical
and laboratory data and is used in the United States for
public health surveillance [38]. Owing to the somewhat
different clinical manifestations and the very different
serologic response to B. burgdorferi, there are currently
no generally accepted diagnostic criteria for Lyme
disease in Europe.
The characteristic clinical findings, together with a history
of tick exposure in areas where Lyme disease is endemic,
supported by the detection of antibodies against
B. burgdorferi by ELISA or western blot, are the most
important elements for the diagnosis of Lyme disease
[21–23,38].
Serology
Serological analyses for antibodies against B. burgdor-
feri are usually performed when Lyme disease is sus-
pected. The recommended procedure is to first use an
ELISA and then to use western blotting for the confirma-
tion of positive ELISA results [21–23,38]. The develop-
ment of an antibody response to B. burgdorferi infection
in untreated patients is well described. IgM antibodies
become detectable 3–4 weeks after the infection, peak
after 6–8 weeks, and subsequently decline. IgG antibod-
ies appear 6–8 weeks after the infection and remain
detectable for many years [21]. It is important to note
that both IgG and IgM responses may persist for longer
than 10 years even after successful antibiotic treatment
[21].
The CDC issued recommendations for test performance
and interpretation for the serologic diagnosis of Lyme
disease [39]. The sensitivity, specificity and reproducibility
of the currently available commercial tests are poor. Sero-
logical testing in general is therefore not clinically useful if
the pretest probability of Lyme disease is less than 0.20 or
greater than 0.80, and the American College of Physicians
has issued recommendations for the cost-effective use of
serological testing [40].
The situation in Europe is even more complicated because
there all three species of B. burgdorferi sensu lato can
cause Lyme disease. The serological response in Euro-
pean Lyme disease patients consequently differs from that
in their American counterparts and there are currently no
generally accepted criteria for the serological diagnosis of
Lyme disease.
Asymptomatic infection
The interpretation of serological data is further compli-
cated by the fact that many inhabitants of areas endemic
for Lyme disease are seropositive yet lack any history or
symptoms of Lyme disease [21]. The frequency of asymp-
tomatic infection may be considerable. In one Swedish
study, more than one-half of the people who were
seropositive by ELISA could not recall any symptoms sug-
gestive of Lyme disease [41]. When the vaccine against
Lyme disease was tested in a prospective clinical trial,
137 of the placebo recipients seroconverted on western
blotting during the 2-year observation period. Twenty-eight
of those recipients (20%) did not show any clinical symp-
toms of Lyme disease [42].
Culture, DNA detection
The culture of B. burgdorferi from patient specimens
proves the diagnosis of Lyme disease but is difficult to
perform and rarely attempted for diagnostic purposes
[21]. PCR allows the reliable detection of B. burgdorferi
DNA in synovial fluid [29] or synovial tissue [30] from
patients with Lyme arthritis, and in the cerebrospinal fluid
from patients with early central nervous system manifesta-
tions of Lyme disease [43]. However, there is consider-
able interlaboratory variation in the results and PCR
detection of B. burgdorferi DNA is currently not consid-
ered a routine method [21,22].
Treatment
The Infectious Diseases Society of America has recently
issued detailed treatment recommendations [44]. Briefly
summarized, doxycycline (orally, 2 × 100 mg/day over
2–3 weeks) is the first choice in early infection (EM) if
there are no contraindications [21,22,44]. For EMpatients, intravenous therapy offers no benefit over the
recommended oral treatment with doxycycline [45].
Neurological symptoms, regardless of whether early (e.g.
facial palsy) or late (e.g. encephalomyelitis), should usually
be treated with ceftriaxone (2 g/day intravenously for
2–4 weeks). Acute neuroborreliosis usually resolves within
several weeks following this treatment, whereas the reso-
lution of chronic neuroborreliosis may take some months
[21,22,44].
Cardiac disease (i.e. atrioventricular block) should be
treated intravenously, similar to neuroborreliosis [21,22,44].
Lyme arthritis should be treated for 30–60 days with doxy-
cycline (200 mg/day orally) or with ceftriaxone (2 g/day
intravenously for 2–4 weeks) [21–23,44]. One study
found the subsequent development of neuroborreliosis
which required ceftriaxone treatment more frequently in
those patients who had been treated with doxycycline
than in those who had been treated with ceftriaxone [33].
If Lyme arthritis persists despite the appropriate antibiotic
treatment and if PCR analysis of the patient’s synovial fluid
is negative, nonsteroidal anti-inflammatory drugs and pos-
sibly arthroscopic synovectomy can be beneficial [21,23].
Long-term outcome
A small percentage of patients who have had Lyme
disease experience an array of chronic symptoms, includ-
ing myalgia, arthralgia, fatigue, and cognitive impairment,
that persist even after the appropriate antibiotic therapy of
Lyme disease. Such symptoms may persist for many
years, resulting in a severely diminished health-related
quality of life for these patients [46,47]. This syndrome,
which shares some features with chronic fatigue syn-
drome and fibromyalgia, has been termed ‘chronic Lyme
disease syndrome’ or ‘post Lyme disease’. The reasons for
the persistence of these symptoms are currently unclear
and could include persistent or slowly resolving infection,
self-perpetuating chronic inflammation or autoimmunity
after the spirochetes have been eradicated, and perma-
nent tissue damage caused by the infection or the immune
response against it. The frequency, diagnosis, pathophysi-
ology, and appropriate treatment of ‘post Lyme disease’
have been a highly contentious issue for more than a
decade. A number of clinical studies have recently tried to
determine the long-term outcome of patients with Lyme
disease. Overall, these studies indicate an excellent prog-
nosis for people with Lyme disease [25,48–55]. Patients
in whom antibiotic treatment for facial palsy had been
delayed are more likely to develop chronic symptoms, indi-
cating that early dissemination of the infection into the
central nervous system might be a risk factor [49,53,55].
Children seem to be at lower risk than adults for ‘post
Lyme disease’ [50,52]. Importantly, when persons with
previous Lyme disease were compared with age-matched
controls, pain and fatigue were reported at the same
frequency in both groups [52–55].
Lyme disease, and especially the possibility of chronic
sequelae, continues to receive massive publicity, resulting
in an irrationally exaggerated anxiety about the risk of
chronic complications from Lyme disease [56]. Partly due
to this anxiety there is an overdiagnosis of Lyme disease,
and people with nonspecific symptoms such as myalgia,
arthralgia, or fatigue are frequently misdiagnosed as
having Lyme disease [56–59]. Even worse, these patients
are frequently subjected to prolonged antibiotic treatment
that can cause considerable and sometimes lethal side
effects [60,61]. Two recent randomized, controlled clinical
trials tested the efficacy of prolonged antibiotic treatment.
One was performed in patients who were seropositive for
antibodies against B. burgdorferi, and the other was per-
formed in patients who were seronegative. Treatment con-
sisted of either 2 g ceftriaxone intravenously daily for
30 days, followed by 200 mg doxycycline orally daily, or
the matching intravenous and oral placebos. Ninety days
of antibiotic treatment did not improve the symptoms more
than 90 days of placebo [62]. Prolonged antibiotic treat-
ment for suspected ‘chronic Lyme disease syndrome’ is
therefore expensive, ineffective, burdened with side
effects and should be avoided.
From infection to autoimmunity? 
Lessons from Lyme disease
Abundant clinical, epidemiological, and experimental evi-
dence suggest autoimmunity as a potential sequel of infec-
tion [63–65]. At the same time, one should not gloss over
the paucity of evidence directly implicating infection as the
cause of any of the important candidate autoimmune
diseases. Are the late neurological manifestations of Lyme
disease or the treatment-resistant form of Lyme arthritis
autoimmune diseases triggered by the infection with
B. burgdorferi? The possible immunopathology of the
chronic neurological manifestations of Lyme disease has
recently been reviewed [66]. In the present paper, we shall
focus on the treatment-resistant form of Lyme arthritis. As
already detailed (see ‘Lyme arthritis’), clinical evidence sug-
gests that the ongoing synovial inflammation in patients
with treatment-resistant Lyme arthritis may be caused by
factors other than persistent B. burgdorferi infection [29,
31–35]. Ideas about the path from infection to autoimmu-
nity divide into two groups: antigen specific, and antigen
nonspecific. For the first set of ideas, what is important is T
cell epitopes. The hypothesis of molecular mimicry predicts
that microbial peptide sequences occasionally mimic
sequences in the host. Once T cells respond to the micro-
bial peptide, the hitherto peaceful self-antigen is also rec-
ognized and disease ensues [64]. The antigen nonspecific
set of ideas assumes inflammatory cytokines to be the
major culprits. One example would be hypersensitivity that
develops to traces of persistent antigen [63,65].
Available online http://arthritis-research.com/content/4/1/020
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
eMolecular mimicry and the pathogenesis of treatment-
resistant Lyme arthritis
Both HLA-DR4 and a T cell response against B. burgdor-
feri OspA are associated with the treatment-resistant form
of Lyme arthritis [32,35]. Therefore, the HLA-DR4-
restricted response to B. burgdorferi OspA has been sus-
pected to trigger chronic synovitis via molecular mimicry.
Compatible with this hypothesis, it was shown that T cells
from the synovial fluid of patients with treatment-resistant
Lyme arthritis recognized both an immunodominant OspA
epitope and a highly homologous peptide derived from
LFA-1 [67]. This is similar to the original report of cross-
reactive T cells that recognize both a microbial peptide
and a highly homologous self-peptide [68], which has
since been confirmed by a number of investigators in dif-
ferent systems [69,70]. In several instances, autoimmunity
was elicited by immunization of experimental animals with
such cross-reactive peptides [71], albeit at much reduced
incidence and severity or only at significantly higher
antigen doses than the homologous self-antigen [64,65].
Novel techniques such as combinatorial peptide libraries
have more recently been used for the study of T cell cross-
reactivity. Several different groups have demonstrated that
T cell recognition of multiple different peptides occurs
much more frequently than previously assumed and that
sequence similarity is not a prerequisite for such cross-
recognition [72–75]. One example is a human T cell clone
that was raised against B. burgdorferi OspC and that rec-
ognized a large number of microbial and human peptides
[74]. Another example showed HLA-DR4-restricted T cell
hybridomas raised against OspA that recognized a large
number of murine or human peptides, including some that
are ubiquitously exposed to the immune system (e.g. a
peptide derived from 4-1BB ligand) or known targets of
autoimmune responses (e.g. peptides derived from Pro-
Insulin or the SS-B antigen) [75]. Given this unexpected
degree of T cell cross-reactivity, why does autoimmunity
not occur much more frequently? Several regulatory
mechanisms normally prevent cross-reactive T cells from
causing injury [65]. First, both the microbial peptide and
the self-peptide must be processed and presented by
antigen presenting cells. Also, the self-antigen must be
present at high enough concentrations and the T cells at
high enough numbers. Third, the T cells must receive the
appropriate co-stimulatory signals from antigen presenting
cells to produce the proinflammatory cytokines required
for tissue damage rather than protective cytokines. Fourth,
the T cells must be capable of migrating to the tissue
where the cross-reactive self-antigen is expressed and
must escape immunoregulation [65]. Finally, some degree
of autoreactivity seems to be necessary for the survival of
naive T cells and possibly also for memory T cells [65].
The idea that cross-reactivity between one particular
microbial peptide and one particular self-peptide is indica-
tive of pathogenicity is thus probably too simple. Neverthe-
less, molecular mimicry remains one attractive hypothesis
for the pathogenesis of autoimmune disease. For example,
microbial peptides might help to maintain the pool of
memory T cells specific for an autoantigen. Furthermore,
persistent or recurrent infections could bring the number
of autoreactive T cells over a critical threshold, thereby
supporting the development of autoimmune disease.
Cytokines, innate immunity
Mononuclear cells or T cell clones derived from the syn-
ovial fluid of patients with Lyme arthritis produce a Th1
cytokine pattern [66,76,77], and one study reported a
stronger Th1 dominance in patients with treatment-resis-
tant arthritis than in patients with treatment-responsive
arthritis [77]. In mice, B. burgdorferi can induce Th1 phe-
notype development in naive Th cells [78], and early data
seemed to indicate an association of Th1 responses with
susceptibility to arthritis in murine models (reviewed in
[66]). More recently, however, it has become clear that
there is no clear correlation between Th1 or Th2
responses and susceptibility to Lyme arthritis in murine
models of the disease [79].
In addition, cytokines such as IL-1β, IL-6, IL-10, IL-11, or
IL-12 that are produced by cells of the innate immune
system have been implicated in the regulation of arthritis
severity in patients or animal models (reviewed in [63,66]).
B. burgdorferi lipoproteins such as OspA are mitogenic
for B cells and potently activate cells of the innate immune
system via their binding of Toll like receptor-2 [16,17].
B. burgdorferi thus induces, in host cells, the production
of IL-1β, IL-6, IL-10, IL-12, and tumor necrosis factor-α
(reviewed in [63,66]). B. burgdorferi OspA, via its activa-
tion of the innate immune system, also induces the differ-
entiation of Th cells that co-express IL-17 and tumor
necrosis factor-α both in mice and in humans [80]. IL-17
is a proinflammatory cytokine in candidate autoimmune
diseases such as rheumatoid arthritis [81]. To date, micro-
bial lipopeptides are the only currently known physiologi-
cal stimulus for IL-17 production [80]. IL-17 in turn
induces the production of other proinflammatory media-
tors such as IL-6 [81]. The reciprocal induction/enhance-
ment of IL-17 and IL-6 could therefore contribute to
infection-induced immunopathology of chronic inflamma-
tory diseases such as treatment-resistant Lyme arthritis.
Altogether, it is likely that antigen-nonspecific mechanisms
mediate, perhaps in synergy with antigen-specific mecha-
nisms, the immunopathology that finally leads to treatment-
resistant Lyme arthritis in susceptible patients.
Prevention
Exposure prophylaxis
Several more or less practicable prophylactic measures
have been suggested to avoid tick bites, including the
Arthritis Research    Vol 4 No 1 Kamradtcomplete avoidance of wooded areas, simple physical
measures such as wearing long sleeves and long pants
that are tucked into the socks, and drastic measures such
as area application of insecticides [82]. Tick and insect
repellents are frequently recommended. However, repel-
lents that contain N,N-diethylmetatoluamide need to be
applied every 1–2 hours to maintain effectiveness and
their use has resulted in serious neurological complica-
tions, including encephalopathy, seizures, coma, and
death in children [83,84]. Permethrin can be sprayed on
clothing and kills ticks but should not be applied to skin
due to its possible carcinogenicity [85]. In infested areas,
daily careful screening for possible tick bites seems to be
the most realistic and useful prophylactic measure. This is
further supported by a number of experimental and obser-
vational data that indicate ticks need to be attached to the
host for at least 24 to >50 hours for transmission of
B. burgdorferi to occur [19,86–88]. Vigilance for tick bites
is indicated not only to protect against B. burgdorferi
infection, but also against other tick-borne infections [87].
Immunization
A number of B. burgdorferi proteins including OspA
[89,90], OspB [91], OspC [92], P35 and P37 [93], and
decorin binding protein A [94] can induce protective anti-
body responses in experimental animals. Among these pro-
teins, only recombinant lipidated OspA is currently licensed
by the Food and Drug Administration (FDA) as a human
vaccine. The OspA vaccine has a unique mode of action.
When a tick feeds on an OspA-immunized host, the serum
antibodies against OspA kill the spirochetes in the tick’s
midgut [95]. These antibodies also block the migration of
B. burgdorferi from the tick’s midgut to the salivary glands
at titers that are considerably lower than those needed to
kill the spirochetes. The OspA vaccine is thus an arthro-
pod-specific transmission-blocking vaccine [96].
Two vaccines consisting of recombinant lipidated OspA
have been studied in large clinical trials [42,97], each
involving more than 10,000 participants. Both studies had
very similar designs and outcomes. A total of 10,936 sub-
jects aged 15–70 years who lived in 10 different states of
the United States where Lyme disease is endemic partici-
pated in the study that led to the approval of LYMErix™ by
the FDA [42]. Of these subjects, 5469 received the
vaccine consisting of recombinant lipidated OspA
adsorbed to aluminum hydroxide in PBS and 5467
received placebo (i.e. alum in PBS without OspA). Injec-
tions were given at entry, 1 month later and 12 months
after the first injection. Within the first year of the study, 22
of the vaccine recipients and 43 of the placebo recipients
developed definite Lyme disease (i.e. clinical symptoms
indicative of Lyme disease [usually EM] plus seroconver-
sion). Within the second year, 16 vaccine recipients and
66 placebo recipients had definite Lyme disease [42]. The
vaccine efficacy was therefore 49% (95% confidence
interval, 15–69%) in the first year. In the second year, after
the booster injection, the vaccine efficacy increased to
76% (95% confidence interval, 58–86%). Within the
vaccine group, two subjects had asymptomatic infection
(seroconversion without clinical symptoms) in the first year
of the study and none in the second year. In contrast, 13
of the placebo recipients had seroconversion in the first
year and 15 in the second year of the study. The vaccine’s
efficacy was correlated with the antibody responses to the
protective epitope of OspA, which is recognized by a
monoclonal antibody called LA-2 [42]. The vaccine recipi-
ents reported significantly more soreness, redness, or
swelling at the injection site (~25%) than the placebo
recipients (~8%). Within the first 30 days after receiving
the injections, there were also more systemic side effects
such as arthralgia, headache, myalgia, fatigue, or fever in
the vaccine group (19.4%) than in the placebo group
(15.1%). In contrast, there was no difference between the
two groups in the frequency of late systemic side effects
such as arthralgia [42].
The other clinical trial, which tested a slightly different
OspA preparation and involved a total of 10,305 subjects,
had very similar results [97]. Both vaccines were thus
found to be safe and effective in the prevention of Lyme
disease, and one vaccine (LYMErix™) was approved in
1998 by the FDA for use in persons older than 16 years.
The current immunization schedule consists of three injec-
tions of recombinant lipidated OspA at baseline, and 1
and 12 months later. The CDC published recommenda-
tions for the use of the OspA vaccine [98].
The duration of protection is currently unknown and addi-
tional booster injections may be necessary. The incidence
of Lyme disease is higher in children than in adults [7–9],
and tetracyclins are contraindicated in small children. The
OspA vaccine is immunogenic in children [99].
Previous studies both in patients with Lyme arthritis and in
experimental animal models raised the possibility that an
immune response against OspA might be detrimental and
could perhaps trigger autoimmune synovitis [34,35,67,
100,101]. In the two aforementioned clinical trials,
however, there were no significant increases in the fre-
quency of arthritis in vaccinees [42,97]. Very rare side
effects of any vaccine would not be detected even in
careful clinical studies, as recently illustrated by experi-
ence with a rotavirus vaccine [102]. The fact that
~1.5 million doses of the OspA vaccine have been admin-
istered and there was no post-licensure discovery of a
serious adverse effect should assuage fears that the
vaccine might provoke arthritis.
In times of economic pressure on health care providers, it
is prudent to ask whether the Lyme vaccine is cost-effec-
tive. In the study that led to the FDA approval of the OspA
Available online http://arthritis-research.com/content/4/1/020
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evaccine, 166 doses had to be administered to prevent one
infection with B. burgdorferi (seroconversion with or
without clinical symptoms of Lyme disease). The clinical
trials were performed in areas of the United States in
which Lyme disease is endemic [42,97]. In areas in which
the incidence of Lyme disease is lower, more doses of the
vaccine would have to be administered to prevent one
infection. At an estimated cost to the pharmacist of $61.25
per dose [103], the study data translate into more than
$10,000 per prevented infection. Treatment of patients
who present with early symptoms of Lyme disease with
doxycycline orally is cheap and effective. On the contrary,
vaccination will also prevent late manifestations that are
more difficult to treat and may occur if early manifestations
such as EM are not recognized. Furthermore, the cost to
prevent one infection could be much lower than the calcu-
lated $10,000 if the protection afforded by the vaccine
lasted for more than 2 years, which is possible. Finally, the
potentially immense costs of overdiagnosis and overtreat-
ment for suspected Lyme disease could be prevented by
vaccination. Thus, it is currently difficult to determine
whether the Lyme vaccine is cost-effective. In an attempt to
calculate the cost-effectiveness of vaccinating against
Lyme disease, a group of authors from the CDC concluded
that vaccination was cost-effective for people whose
annual risk to contract Lyme disease exceeds 1% [104].
The OspA vaccine is not available in Europe. Lyme disease
in the United States is exclusively caused by B. burgdorferi
sensu stricto, whereas in Europe B. burgdorferi  sensu
stricto, B. garinii, and B. afzelii all cause Lyme disease.
There is considerable OspA sequence heterogeneity
among European isolates [105], thus preventing the effec-
tiveness of an OspA vaccine that is based on one single
sequence from B. burgdorferi sensu stricto [106]. A poly-
valent vaccine, composed of several different OspC, is cur-
rently undergoing clinical trials in Europe.
Secondary prevention?
If a person who is not immunized against Lyme diseases
recognizes a tick bite, should they receive antibiotic treat-
ment? Even in areas where Lyme disease is endemic,
such as Connecticut, the risk of developing Lyme disease
following recognized tick bites is only 1–3% [103,107,
108]. Based on this low risk and on the possible side
effects of treatment with doxycycline, the Infectious Dis-
eases Society of America has issued a recommendation
that tick-bitten persons should not routinely receive con-
ventional antibiotic treatment [44]. A recent study demon-
strated that a single dose of 200 mg doxycycline orally
was 87% effective in preventing Lyme disease if adminis-
tered within 72 hours after the tick bite [103]. Only 3% of
the placebo recipients in this study, which was performed
in Westchester County, New York, where the incidence of
Lyme disease is arguably the highest in the world, devel-
oped Lyme arthritis. Thus, 40 doses of doxycycline had to
be administered to prevent one case of Lyme disease.
Again, this number would be considerably higher in areas
with a lower incidence of Lyme disease. In addition, clini-
cal experience shows that most cases of Lyme disease
result from unrecognized tick bites. This would further
decrease the effect of prophylactic doxycycline adminis-
tration on the incidence of Lyme disease.
Summary and outlook
The development of an effective vaccine against Lyme
disease and the improved understanding of the long-term
outcome of Lyme disease can be considered the most
important advances in the field over the past several years.
The sequencing of the B. burgdorferi genome has opened
the door for an increased understanding of the biology of
B. burgdorferi and its rapid adaptation to different hosts
and environments.
Treatment for patients with acute manifestations of Lyme
disease is well established and effective. Understanding
the pathophysiology of chronic neuroborreliosis and treat-
ment-resistant Lyme arthritis are both major challenges
and a prerequisite for the eventual development of effec-
tive treatments for these conditions. While there is little
doubt that infection-induced immunopathology has an
important role in treatment-resistant Lyme arthritis, the jury
is still out on the exact pathways that lead from infection to
chronic inflammation and possibly autoimmunity. As in
many other areas of immunology, a period of intense
research on antigen-specific T cells seems to be supple-
mented now by a view on the innate immune system’s role
in mediating both protection and immunopathology.
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